← Back to screener

Keros Therapeutics, Inc. KROS

Rank #1958 · Nasdaq · $0.2B market cap
Audited by Deloitte & Touche LLP, no going-concern flag in the latest filing.
Score
37.9
P/E
-1.2
P/B
0.66
ROE
-56.4%
Op. Margin
–%
Debt Ratio
13%

Health Check — percentile rank within this universe, based on the latest annual filing

Valuation ★★☆☆☆
Average

P/E -1.2x, P/B 0.66x. Ranks in the top 52% of the universe.

Profitability ★☆☆☆☆
Poor

ROE -56.4%. Ranks in the top 90% of the universe.

Safety ★★★★☆
Excellent

Debt ratio 13%. Ranks in the top 11% of the universe. Under 100% is generally considered a safe level.

Growth –
No data

Not enough historical filings to compute year-over-year growth yet.

Safety is the relative strength · Profitability is the relative weakness (relative to this universe).

Financials annual, from SEC 10-K filings

FYRevenueOp. IncomeNet IncomeEquityOp. Margin%Debt%
2020$0.0B$-0.0B$-0.0B$-0.0B-105.6-146
2021$0.0B$-0.0B$-0.0B$-0.0B–-40
2022$0.0B$-0.1B$-0.1B$0.3B-280.55
2023$0.0B$-0.1B$-0.1B$0.3B-280.511
2024$0.0B$-0.1B$-0.1B$0.2B–16
2025$0.0B$-0.2B$-0.2B$0.3B–13

← See the full screener